Skip to main content
Quest Diagnostics

Associations of Serum Per- and Polyfluoroalkyl Substances (PFAS) Levels with Clinical Indicators in a Clinical Patient Cohort

ADLM 2026

Association for Diagnostics and Laboratory Medicine

Anaheim, CA, June 26-30, 2026,

Poster presentation: Associations of Serum Per- and Polyfluoroalkyl Substances (PFAS) Levels with Clinical Indicators in a Clinical Patient Cohort

Authors: Wen Dui

Medical Specialty: Prescription Drug Monitoring, Toxicology

Related content

Audio Podcast
PFAS: Understanding the Risks and the Role of Testing
Publication
Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM)
Conference Presentation
Correlation Between PFAS Forever Chemical Concentrations in Remnant Serum and Public Drinking Water
Conference Presentation
Development and Validation of the 9 NASEM PFAS Analytes in Serum and NASEM Recommended Summation PFAS Results in Donor Specimens
Conference Presentation
Emerging Environmental Toxins: PFAS Forever Chemicals and Beyond

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.